Irving Vidaurre

853 total citations
28 papers, 725 citations indexed

About

Irving Vidaurre is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Molecular Biology. According to data from OpenAlex, Irving Vidaurre has authored 28 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Irving Vidaurre's work include Growth Hormone and Insulin-like Growth Factors (12 papers), Cancer-related Molecular Pathways (8 papers) and Neuroendocrine Tumor Research Advances (5 papers). Irving Vidaurre is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (12 papers), Cancer-related Molecular Pathways (8 papers) and Neuroendocrine Tumor Research Advances (5 papers). Irving Vidaurre collaborates with scholars based in United States, Hungary and Germany. Irving Vidaurre's co-authors include Andrew V. Schally, Norman L. Block, Ferenc G. Rick, Luca Szalontay, Márta Zarándi, Gábor Halmos, Roberto Pérez‐Castañeda, Károly Szepesházi, Mehrdad Nadji and József L. Varga and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer and The Journal of Urology.

In The Last Decade

Irving Vidaurre

28 papers receiving 712 citations

Peers

Irving Vidaurre

EDM

ONCOL

PRM

Petra Popovics United States

John Apps United Kingdom

Roland Gander Austria

Junming Luo China

Yun Yan United States

Elaine S. Gilmore United States

Ludo Deboel Belgium

Bayard D. Catherwood United States

Mary K. Luidens United States

L Wickert Germany

Petra Popovics United States

Irving Vidaurre

260 ×0.7

EDM

289 ×1.3

96 ×0.5

ONCOL

92 ×0.8

PRM

51 ×0.7

Citations per year, relative to Irving Vidaurre Irving Vidaurre (= 1×) peers Petra Popovics

Countries citing papers authored by Irving Vidaurre

Since Specialization

Citations

This map shows the geographic impact of Irving Vidaurre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irving Vidaurre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irving Vidaurre more than expected).

Fields of papers citing papers by Irving Vidaurre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irving Vidaurre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irving Vidaurre. The network helps show where Irving Vidaurre may publish in the future.

Co-authorship network of co-authors of Irving Vidaurre

This figure shows the co-authorship network connecting the top 25 collaborators of Irving Vidaurre. A scholar is included among the top collaborators of Irving Vidaurre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irving Vidaurre. Irving Vidaurre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schally, Andrew V., George Theodoropoulos, Wei Sha, Irving Vidaurre, & Medhi Wangpaichitr. (2025). A 50-year journey in the development of treatment for benign prostatic hyperplasia. PubMed. 11(1). 41–41. 1 indexed citations

Cui, Tengjiao, Medhi Wangpaichitr, Andrew V. Schally, et al.. (2023). Alveolar epithelial cell growth hormone releasing hormone receptor in alveolar epithelial inflammation. Experimental Lung Research. 49(1). 152–164. 7 indexed citations

Cai, Renzhi, Xianyang Zhang, Tengjiao Cui, et al.. (2021). Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity. Peptides. 150. 170716–170716. 21 indexed citations

Zhang, Xianyang, et al.. (2018). Inhibition of experimental small‐cell and non‐small‐cell lung cancers by novel antagonists of growth hormone‐releasing hormone. International Journal of Cancer. 142(11). 2394–2404. 27 indexed citations

Dubovy, Sander R., Maria Paula Fernandez, Jose J. Echegaray, et al.. (2017). Expression of hypothalamic neurohormones and their receptors in the human eye. Oncotarget. 8(40). 66796–66814. 10 indexed citations

Szalontay, Luca, Andrew V. Schally, Petra Popovics, et al.. (2014). Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. Cell Cycle. 13(17). 2790–2797. 29 indexed citations

Jászberényi, Miklós, Andrew V. Schally, Norman L. Block, et al.. (2013). Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro. Targeted Oncology. 8(4). 281–290. 23 indexed citations

Jászberényi, Miklós, Ferenc G. Rick, Petra Popovics, et al.. (2013). Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists. Proceedings of the National Academy of Sciences. 111(2). 781–786. 13 indexed citations

Pérez‐Castañeda, Roberto, et al.. (2012). Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers. Oncotarget. 3(9). 988–997. 43 indexed citations

10.

Szalontay, Luca, Ronald J. Benveniste, Andrew V. Schally, et al.. (2012). Inhibitory Effects of GHRH Antagonists on Human GH-Secreting Adenoma Tissue. Neuroendocrinology. 96(1). 81–88. 5 indexed citations

11.

Szepesházi, Károly, Andrew V. Schally, Ferenc G. Rick, et al.. (2012). Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II. Anti-Cancer Drugs. 23(9). 906–913. 4 indexed citations

12.

Rick, Ferenc G., Luca Szalontay, Andrew V. Schally, et al.. (2012). Combining Growth Hormone-Releasing Hormone Antagonist With Luteinizing Hormone-Releasing Hormone Antagonist Greatly Augments Benign Prostatic Hyperplasia Shrinkage. The Journal of Urology. 187(4). 1498–1504. 32 indexed citations

13.

Klukovits, Anna, Andrew V. Schally, Luca Szalontay, et al.. (2011). Novel antagonists of growth hormone‐releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Cancer. 118(3). 670–680. 30 indexed citations

14.

Rick, Ferenc G., Andrew V. Schally, Norman L. Block, et al.. (2011). Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proceedings of the National Academy of Sciences. 108(9). 3755–3760. 70 indexed citations

15.

Banks, William A., John E. Morley, Susan A. Farr, et al.. (2010). Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice. Proceedings of the National Academy of Sciences. 107(51). 22272–22277. 43 indexed citations

16.

Pozsgai, Éva, Andrew V. Schally, Márta Zarándi, et al.. (2010). The effect of GHRH antagonists on human glioblastomas and their mechanism of action. International Journal of Cancer. 127(10). 2313–2322. 16 indexed citations

17.

Rick, Ferenc G., Andrew V. Schally, Norman L. Block, et al.. (2010). LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. The Prostate. 71(7). 736–747. 71 indexed citations

18.

Bellyei, Szabolcs, Andrew V. Schally, Márta Zarándi, et al.. (2010). GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Letters. 293(1). 31–40. 38 indexed citations

19.

Hohla, Florian, Stefan Buchholz, Andrew V. Schally, et al.. (2009). GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle. 8(19). 3149–3156. 35 indexed citations

20.

McCarthy, Micheline, et al.. (2006). Maturing neurons are selectively sensitive to human immunodeficiency virus type 1 exposure in differentiating human neuroepithelial progenitor cell cultures. Journal of NeuroVirology. 12(5). 333–348. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact